This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

The WHO guidance aims to spur development of in vitro diagnostic tests that can quickly and accurately identify serious ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over ...

Live from Morristown: Real-world US study confirms BEYFORTUS shields infants from RSV, cutting illness rates and hospitalizations.

MORRISTOWN, NJ, USA I July 22, 2025 I The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory syncytial virus (RSV) preventive developed by French drugmaker Sanofi and ...